46 results on '"Nasrallah, Gheyath K."'
Search Results
2. A customizable multiplex protein microarray for antibody testing and its application for tick-borne and other infectious diseases
3. A turning point in COVID-19 severity and fatality during the pandemic: A national cohort study in Qatar
4. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: An observational study
5. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta infections
6. High-sensitive detection and quantitation of thyroid-stimulating hormone (TSH) from capillary/fingerstick and venepuncture whole-blood using fluorescence-based rapid lateral flow Immunoassay (LFIA)
7. Effect of BNT162b2 antigen dosage on protection against SARS-CoV-2 omicron infection
8. Enhancing the sensitivity of rapid antigen detection test (RADT) of different SARS-CoV-2 variants and lineages using fluorescence-labeled antibodies and a fluorescent meter
9. Protection against reinfection with SARS-CoV-2 omicron BA.2.75*sublineage
10. Performance evaluation of new fluorescent-based lateral flow immunoassay for quantification of HbA1c in diabetic patients
11. Immune protection against SARS-CoV-2 re-reinfection and immune imprinting
12. Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar
13. Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants
14. Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar
15. High but Short-lived anti-SARS-CoV2 neutralizing, IgM, IgA, and IgG levels among mRNA-vaccinees compared to naturally-infected participants
16. Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar
17. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
18. Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections
19. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
20. Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar
21. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar
22. Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant
23. Validation of a novel fluorescent lateral flow assay for rapid qualitative and quantitative assessment of total anti-SARS-CoV-2 S-RBD binding antibody units (BAU) from plasma or fingerstick whole-blood of COVID-19 vaccinees
24. Performance evaluation of novel fluorescent-based lateral immune flow assay (LIFA) for rapid detection and quantitation of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals
25. Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design
26. Waning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar
27. Characterizing the effective reproduction number during the COVID-19 epidemic: Insights from Qatar’s experience
28. Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals
29. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
30. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar
31. SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients
32. Severity, criticality, and fatality of the SARS-CoV-2 Beta variant
33. Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections
34. Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection
35. Epidemiological impact of prioritizing SARS-CoV-2 vaccination by antibody status: Mathematical modeling analyses
36. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
37. Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting
38. No evidence of significant cross-reactivity between the dengue virus (DENV) and SARS-CoV-2 IgG antibodies
39. Effect of multiple freeze-thaw cycles on detection of anti-SARS-CoV-2 IgG antibodies
40. COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar
41. Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2
42. SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks
43. Epidemiological impact of prioritizing SARS-CoV-2 vaccination by antibody status: Mathematical modeling analyses
44. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
45. Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting
46. Distinct antibody repertoires against endemic human coronaviruses in children and adults
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.